- Home
- ALEX vs ORKA Comparison
ALEX vs ORKA Comparison
Compare ALEX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEX
- ORKA
- Stock Information
- Founded
- ALEX 1870
- ORKA 2004
- Country
- ALEX United States
- ORKA United States
- Employees
- ALEX N/A
- ORKA N/A
- Industry
- ALEX Real Estate Investment Trusts
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALEX Real Estate
- ORKA Health Care
- Exchange
- ALEX Nasdaq
- ORKA Nasdaq
- Market Cap
- ALEX 1.2B
- ORKA 1.2B
- IPO Year
- ALEX N/A
- ORKA N/A
- Fundamental
- Price
- ALEX $15.76
- ORKA $28.49
- Analyst Decision
- ALEX Buy
- ORKA Strong Buy
- Analyst Count
- ALEX 2
- ORKA 8
- Target Price
- ALEX $24.00
- ORKA $44.38
- AVG Volume (30 Days)
- ALEX 431.8K
- ORKA 453.1K
- Earning Date
- ALEX 10-30-2025
- ORKA 11-11-2025
- Dividend Yield
- ALEX 5.75%
- ORKA N/A
- EPS Growth
- ALEX 65.09
- ORKA N/A
- EPS
- ALEX 1.01
- ORKA N/A
- Revenue
- ALEX $226,062,000.00
- ORKA N/A
- Revenue This Year
- ALEX N/A
- ORKA N/A
- Revenue Next Year
- ALEX $2.00
- ORKA N/A
- P/E Ratio
- ALEX $15.56
- ORKA N/A
- Revenue Growth
- ALEX N/A
- ORKA N/A
- 52 Week Low
- ALEX $15.51
- ORKA $5.49
- 52 Week High
- ALEX $19.97
- ORKA $29.46
- Technical
- Relative Strength Index (RSI)
- ALEX 29.39
- ORKA 66.00
- Support Level
- ALEX $15.52
- ORKA $25.57
- Resistance Level
- ALEX $17.07
- ORKA $29.25
- Average True Range (ATR)
- ALEX 0.28
- ORKA 1.77
- MACD
- ALEX -0.07
- ORKA -0.35
- Stochastic Oscillator
- ALEX 15.35
- ORKA 71.01
About ALEX Alexander & Baldwin Inc. REIT Holding Company
Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.